Clinical Trials: Page 2

UniQure's gene therapy for hemophilia B meets goal in key study

The results are first to emerge from a late-stage test of a hemophilia B gene therapy, and show UniQure's treatment can restore clotting protein levels to mild or even near normal levels.

By Ned Pagliarulo • Nov. 19, 2020

New AstraZeneca data offer latest hint coronavirus vaccines may protect elderly

Results published Thursday add to hopes the experimental shots now in testing won't only work for young, healthy people. More details are needed, though.

By Ben Fidler • Nov. 19, 2020

Explore the Trendline➔

Trendline

Inside the global race for a coronavirus vaccine

Some 29 vaccine candidates are now in clinical studies. Early results from five leading efforts are encouraging, suggesting researchers are on the right track despite rapid acceleration of testing.

By BioPharma Dive staff

New coronavirus vaccine data bolster Pfizer, BioNTech claims of strongly effective shot

Reaching the main goal of their large trial, Pfizer and BioNTech reported 162 cases of COVID-19 among participants who received a placebo, and just eight for those who were vaccinated. 

By Ned Pagliarulo • Nov. 18, 2020

Trial success for 2 coronavirus vaccines backs up early research bets

Positive data from Pfizer and Moderna offer the strongest validation yet of researchers' approach to coronavirus vaccines, but leave several questions still unanswered.

By Ned Pagliarulo , Ben Fidler • Nov. 17, 2020

Stem cell therapy for ALS fails a large clinical trial

The therapy's developer, Brainstorm Therapeutics, blamed the setback on better-than-expected results from placebo-treated patients. The biotech still sees a path forward, however.

By Jacob Bell • Nov. 17, 2020

Moderna says vaccine prevents COVID-19 in large study, adding to hopes for several protective shots

Multiple effective vaccines will likely be needed to end the pandemic. Moderna's study results, which are equally strong as those reported by Pfizer and BioNTech last week, make that outcome more likely.

By Ben Fidler • Nov. 16, 2020

Sponsored by Altasciences

Ligand binding program considerations – the value of preclinical to clinical bioanalytical expertise

Careful selection of a partner CRO can deliver advantages and accelerate your drug development program. 

Sponsored by SAP

5 reasons life sciences needs better clinical trial supply management

A new industry consortium is lining up stakeholders to work together to address long-standing pain points that disrupt clinical trials.

AstraZeneca cancer drug found ineffective for COVID-19

The setback follows disappointing results from companies like Novartis and Sanofi, which have also sought to repurpose existing drugs for COVID-19.

By Kristin Jensen • Nov. 12, 2020

Moderna close to having results from key coronavirus vaccine trial

The fast-accelerating spread of coronavirus in the U.S. has sped up Moderna's timeline for its late-stage vaccine study, which now has sufficient COVID-19 cases for a first look at results.

By Ned Pagliarulo • Nov. 12, 2020

Pfizer, BioNTech's strong results give lift to other coronavirus vaccines

The companies' early success helps validate an industry-wide bet to target the coronavirus' spike protein. But differences between each vaccine could still prove crucial.

By Jonathan Gardner • Nov. 11, 2020

Pfizer and BioNTech's coronavirus vaccine works. Here's what we still don't know.

An early analysis found the companies' shot more than 90% effective in preventing COVID-19. Beyond that highly encouraging number, however, there were few other details.

By Ned Pagliarulo , Ben Fidler • Nov. 10, 2020

Amgen's asthma drug delivers a needed win

A late-stage study found Amgen's tezepelumab benefited a variety of patients with severe asthma, results that one analyst called a "best-case outcome."

By Jacob Bell • Nov. 10, 2020

Coronavirus vaccine from Pfizer, BioNTech prevents COVID-19, early results show

An early look at Pfizer and BioNTech's large coronavirus vaccine study found the companies' experimental shot more than 90% effective, an encouraging result that bodes well for others in development.

By Jonathan Gardner • UPDATED: Nov. 9, 2020 at 9:40 a.m.

Novartis rare disease drug, repurposed for COVID-19, fails in late-stage study

The Swiss drugmaker's COVID-19 research efforts now largely rest on the outcome of a recent alliance to develop oral medicines for the new coronavirus.

By Ben Fidler • Nov. 06, 2020

Gene therapy for Duchenne muscular dystrophy: nearing final tests

Sarepta and Pfizer are advancing their experimental treatments into late-stage trials, while others are accelerating research in what's become one of gene therapy's most active fields.

By Ben Fidler • Nov. 05, 2020

Allogene shares sink on early look at an 'off the shelf' CAR-T for myeloma

Results the company will present at a medical meeting, while early, don't appear to meet the high bar set by rival CAR-T cell therapies from Bristol Myers Squibb and Johnson & Johnson. 

By Ben Fidler • Nov. 04, 2020

Bristol Myers bet pays off as psoriasis drug beats Amgen rival in study

While full data were not disclosed, the trial's outcome signals competition for Amgen's Otezla, which Celgene was forced to divest last year as a result of its acquisition by Bristol Myers.

By Ned Pagliarulo • Nov. 03, 2020

AstraZeneca partners with Fusion to test radiopharmaceuticals in cancer

While small in size, the collaboration gives AstraZeneca an entry point into radiopharmaceutical drug research, which was the focus of two Novartis buyouts in recent years.

By Ned Pagliarulo • Nov. 02, 2020

Safety concerns lead Regeneron to halt testing of COVID-19 drug in some patients

A study monitoring board flagged a "potential safety signal" in some hospitalized COVID-19 patients who require breathing support, telling the biotech to modify its study protocol.

By Ben Fidler • Oct. 30, 2020

Lilly antibody drug doesn't help hospitalized COVID-19 patients in NIH study

The results could raise doubts about the ability of synthetic antibody drugs to help patients already very sick with COVID-19.

By Ben Fidler • UPDATED: Oct. 27, 2020 at 11:45 a.m.

Sponsored by Parexel International

Identifying and recruiting patients into rare disease clinical trials: A multi-pronged and customized approach

Learn about strategies for identifying and recruiting rare disease patients. 

By Sarah Glass, Ph.D., Shipra Patel, M.D., & Altair Silva, Parexel • Oct. 27, 2020

Mirati cancer drug results spark hopes of outperforming Amgen's

The biotech's KRAS-blocking pill trails Amgen's sotorasib in development, but early data suggest it might match the bar set by Amgen.

By Jonathan Gardner • Oct. 26, 2020

AstraZeneca, J&J cleared to restart major coronavirus vaccine studies

The U.S. trial of AstraZeneca's shot has been paused over safety concerns since early September, while J&J's was halted in mid-October. 

By Ned Pagliarulo • UPDATED: Oct. 24, 2020 at 2:59 p.m.

At key meeting, FDA advisors debate if early coronavirus vaccine approvals may compromise trials

An emergency clearance is expected for the first vaccine proven effective. But early availability of a shot could jeopardize ongoing studies, and may make tests of other candidates more difficult.

By Ned Pagliarulo • Oct. 23, 2020